Media stories about Recro Pharma (NASDAQ:REPH) have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Recro Pharma earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 45.8783152173751 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of Recro Pharma (NASDAQ:REPH) remained flat at $7.74 during mid-day trading on Wednesday. 63 shares of the company’s stock were exchanged. The stock’s market capitalization is $147.52 million. Recro Pharma has a 12 month low of $5.81 and a 12 month high of $10.17. The company’s 50 day moving average price is $7.44 and its 200 day moving average price is $7.60.

Recro Pharma (NASDAQ:REPH) last posted its earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.48) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.54) by $0.06. The company had revenue of $16.93 million for the quarter, compared to analyst estimates of $14.90 million. Recro Pharma had a negative net margin of 46.75% and a negative return on equity of 56.04%. Equities research analysts anticipate that Recro Pharma will post ($2.35) earnings per share for the current year.

Several research analysts have issued reports on REPH shares. Janney Montgomery Scott cut Recro Pharma from a “buy” rating to a “fair value” rating and dropped their price target for the company from $21.00 to $6.50 in a report on Wednesday, June 14th. Roth Capital set a $20.00 price target on Recro Pharma and gave the company a “buy” rating in a report on Monday, July 31st. Zacks Investment Research raised Recro Pharma from a “hold” rating to a “buy” rating and set a $9.50 price target on the stock in a report on Wednesday, May 17th. Finally, Piper Jaffray Companies set a $11.00 price target on Recro Pharma and gave the company a “buy” rating in a report on Tuesday, July 25th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $13.82.

ILLEGAL ACTIVITY WARNING: “Recro Pharma (REPH) Earning Somewhat Favorable News Coverage, Analysis Shows” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/09/13/recro-pharma-reph-earning-somewhat-favorable-news-coverage-analysis-shows.html.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Insider Buying and Selling by Quarter for Recro Pharma (NASDAQ:REPH)

Receive News & Stock Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related stocks with our FREE daily email newsletter.